The Goldman Sachs Group Raises Enliven Therapeutics (NASDAQ:ELVN) Price Target to $80.00

Enliven Therapeutics (NASDAQ:ELVN) had its target price boosted by investment analysts at The Goldman Sachs Group from $67.00 to $80.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 34.00% from the company’s current price.

Other research analysts also recently issued reports about the company. HC Wainwright upped their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Mizuho boosted their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Finally, Guggenheim initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $80.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $72.67.

Enliven Therapeutics Stock Down 2.3%

NASDAQ:ELVN opened at $59.70 on Thursday. The business’s 50-day simple moving average is $47.81 and its two-hundred day simple moving average is $39.29. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32. The stock has a market cap of $3.64 billion, a PE ratio of -35.75 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Sell-side analysts anticipate that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the sale, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at $2,424,282.56. The trade was a 11.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the transaction, the director owned 41,884 shares in the company, valued at $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 32,036 shares of company stock valued at $1,430,676. 3.00% of the stock is currently owned by insiders.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP lifted its holdings in Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after buying an additional 2,670,000 shares in the last quarter. Siren L.L.C. bought a new position in Enliven Therapeutics in the first quarter worth approximately $29,252,000. Affinity Asset Advisors LLC purchased a new position in Enliven Therapeutics during the 1st quarter worth $23,007,000. TCG Crossover Management LLC bought a new stake in Enliven Therapeutics during the 2nd quarter valued at $9,990,000. Finally, Duquesne Family Office LLC raised its position in Enliven Therapeutics by 104.6% during the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after purchasing an additional 484,405 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.